Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model

Tuesday, May 19, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EPS-3903 is a newly identified oral inhibitor of STAT6, showing significant potential in blocking Th2 inflammation. This compound was tested in a house dust mite-induced asthma mouse model, demonstrating its effectiveness in managing asthma-related inflammation. The findings suggest a promising avenue for treating asthma and related conditions.
Price reaction · baseline $13.45 (2026-05-18 close) · hit pre-market · 1 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • EPS-3903 shows potent and selective inhibition of STAT6.
  • The compound effectively blocks Th2 inflammation.
  • Demonstrated efficacy in a relevant asthma mouse model.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EPS-3903?

EPS-3903 is a potent and selective oral inhibitor of STAT6.

How does EPS-3903 work?

It blocks Th2 inflammation, which is significant in asthma management.

In what model was EPS-3903 tested?

It was tested in a house dust mite-induced asthma mouse model.

What condition does EPS-3903 target?

EPS-3903 targets asthma and related inflammatory conditions.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EPS-3903 STAT6 asthma Th2 inflammation
Last updated: May 19, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →